Opinion · 1 Dec 2025
Conference abstractPublished 27 Feb 2017
The effectiveness of a Cucumis sativus extract (Imunopure gherkin®) in the management of osteoarthritis
University of YaoundÃ?©, Cameroon PhytoQuest Limited, Plas Gogerddan, Aberystwyth, Ceredigion, UK PhytoQuest Limited, Plas Gogerddan, Aberystwyth, Ceredigion, UK Samrat Layout, Arekere, Bangalore, Karnataka, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: The global prevalence of osteoarthritis (OA) is escalating worldwide primarily because of the aging of populations and the rising prevalence of obesity. This study evaluated the ability of IminoPure GherkinÃ?® (IPGÃ?®), a Cucumis sativus extract, to improve knee symptoms in OA. Methodology: A six-month (180 days) randomized, double-blind study was conducted with two groups of patients diagnosed with primary OA of the knee to compare the effects of IPGÃ?® with that of a combination of glucosamine hydrochloride and chondroitin sulphate (GC). One hundred twenty-two (122) OA patients aged 40-75 years with a body-mass index (BMI) of 18-30 kg/m2 were evaluated. The patients received either 10 mg of IPGÃ?® or GC twice daily for 180 days. Pain, stiffness and physical function were assessed in each patient using standard tools (visual analog scale (VAS), Lequesne's Functional Index (LFI), WOMAC at baseline (Day 0) and at Days 7, 30, 60, 90, 120, 150 and 180. Findings: The results were expressed as relative scores in percentages. The GC and IPGÃ?® treatments significantly (p<0.05) and gradually reduced the WOMAC, VAS, and LFI scores by Day 30 from the baseline value. The GK treatment significantly (p<0.05) reduced the WOMAC score by 22.44% at Day 30 and by 70.29% at Day 180. The daily reductions with IPGÃ?® were significantly (p<0.05) higher than that in the GC groups. From magnitude of the reductions, the IPGÃ?® treatment at Day 30 had reduced the WOMAC score by 6 Ã?± 0.18% more than the GC treatment and further reduced it by 28.50 Ã?± 0.14 and 39 Ã?± 0.05% at Day 150 and Day 180, respectively. Additionally, the IPGÃ?® treatment at Day 30 reduced the average VAS scale by 8.6% and 20.77% at Day 180. At Day 30, the IPGÃ?® treatment reduced the average LFI Score by 12.29% and 18.90% at Day 150 and at Day 180, respectively. No adverse events (AEs) were recorded. Conclusion & Significance: Our results indicate the efficacy and potential use of IPGÃ?®, as an anti-OA therapy. It significantly (p<0.05) reduces the WOMAC, VAS, and LFI scores in patients suffering from OA, bringing about an improvement in knee pain, stiffness, and physical function.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmacoeconomics: Open Access.
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Boris G. Kingue Azantsa”
- BylineArticles whose byline prints “Robert Nash”
- BylineArticles whose byline prints “Hazel Sharp”
- BylineArticles whose byline prints “Velmurugan Shanmugham”
